Abstract:Yang Li, Hebin Wang, Kai Wang, Qinglian Hu, Qi Yao, Youqing Shen, Guocan Yu,* and Guping Tang* amphiphilic drug–drug conjugate for cancer therapy, which exhibited excellent anticancer activity in vitro and in vivo.[10] Hao and co-workers confirmed that a combination of three chemotherapy agents (5-fluorouracil, irinotecan, oxaliplatin) proved to be efficient for pancreatic cancer therapy.[11] However, chemotherapy also faces several limitations, including fast blood/renal clearance, poor bioavailability, and multidrug resistance.[12] Furthermore, the shortage of targeting selectivity leads to serious side effects toward normal tissues, greatly limiting their efficacy and clinic applications. Due to its high specificity and low toxicity,[13, 14] small interfering RNA (siRNA) is able to silence almost any target gene after cellular delivery, providing them with great potential for gene therapy for various diseases, including cancer.[15, 16] A variety of siRNA-based therapeutics have been developed, showing great promise in cancer treatments.[17–19] Orphan nuclear receptor TR3/Nur77 is a new therapeutic target for pancreatic cancer therapy, which is reported overexpressed in a panel of human pancreatic tumors (77%), the endogenous TR3 not only facilitates cell growth but also cell survival by repressing apoptosis.[20, 21] siTR3 decreases TR3 mRNA and TR3/Nur77 protein, and this is accompanied by decreasing expression of Bcl-2 and Survivin and induction of cleaved caspase-3 and poly ADP ribose polymerase (PARP) cleavage, confirming the activation of apoptosis.[22, 23] As a result, knocking down TR3 signal pathway is potential to prevent the …

Targeted co‐delivery of PTX and TR3 siRNA by PTP peptide modified dendrimer for the treatment of pancreatic cancer